Imagine Institute Report issue

Foundation Phase 2 Phase 4

Organization Overview

First Clinical Trial
2017
NCT03217643
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

IMAGINE | Imagine Institute

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Enteropathy-Associated T-Cell Lymphoma (Phase 2)

Intestinal Diseases (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Short Bowel Syndrome (Phase 4)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 4